Capsugel Launches an Improved Laboratory -Scale Liquid Capsule Filling and Sealing (CFS) Machine


LONDON, October 9/ - Capsugel, the leading supplier of capsules for the pharmaceutical and dietary supplement industries, today announced the launch of the CFS1200, an improved version of its laboratory-scale Capsule Filling and Sealing system.

This updated machine offers R&D laboratories several significant improvements over its predecessor, the CFS1000, which is currently used extensively by pharmaceutical development scientists to fill and seal capsules with liquid formulations. The CFS1200 utilizes Capsugel's patented LEMS (Liquid Encapsulation Micro-Spray) Technology.

The CFS1200 employs a unique micro-dosing technology, which offers automated capsule filling and sealing for preparation of early stage clinical trial supplies. Specifically designed to allow formulation scientists a better ability to exploit the potential of lipid based or poorly soluble compounds, the CFS1200 helps accelerate the development timeframe and achieve 'Faster Time to First in Man(TM)', or the critical go/no go decision point for new molecules within the pharmaceutical development process.

David Edwards, Capsugel's Director of Pharmaceutical Technology, said "While the CFS1000 has been widely accepted in the industry, our market research and dialogue with customers has identified the need for additional features. The CFS1200 has been developed directly as a result of this feedback, particularly in respect of a higher throughput rate, improved capsule handling and sealing, more accurate temperature control and better cleanability. All of these features are included in the new product".

Keith Hutchison, Vice President of R&D at Capsugel said "Going forward, a key part of Capsugel's strategy is to focus more on providing integrated solutions to customer's problems. The new CFS1200 enables Pharmaceutical R&D departments to overcome some major Formulation Development challenges such as those of poorly soluble drugs and highly potent new molecules. We see the CFS1200 as a key part of our strategy in this area."

The new CFS1200 will be on display on the Capsugel Booth 829, Hall C at the AAPS Exposition in San Antonio, Texas, USA, October 29th- November 2nd 2006. (http://www.aapspharmaceutica.com/meetings/annualmeet/am06/index.asp).

Further information is available at www.capsugel.com

Notes:

Capsugel is the world's leading manufacturer and developer of capsule products, equipment and services for the pharmaceutical and associated healthcare industries, and is a division of Pfizer, Inc.

Source: Capsugel Division of Pfizer

Contact for communications:
William J. Chekan,
Director of Global Marketing,
Capsugel, Div. of Pfizer, Inc.,
Tel: +1-973-385-0185,
FAX: +1-973-385-2317,
E mail: william.chekan@pfizer.com.

Contact for CFS 1200 enquiries:
David Edwards,
Director of Pharmaeutical Technology,
david.edwards2@pfizer.com.
Capsugel Division of Pfizer,
Cambridge Research Centre,
Granta Park,
Great Abington,
Cambridge CB1 6GB, UK,
Tel: +44-1223-598480,
FAX: +44-1223-598070

More from Chemicals & Gases

All Topics